These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 33071973)
1. Clinical, Laboratory, and Treatment Profiles of Silent Corticotroph Adenomas That Have Transformed to the Functional Type: A Case Series With a Literature Review. Zheng G; Lu L; Zhu H; You H; Feng M; Liu X; Dai C; Yao Y; Wang R; Zhang H; Sun X; Lu Z Front Endocrinol (Lausanne); 2020; 11():558593. PubMed ID: 33071973 [No Abstract] [Full Text] [Related]
2. Clinical Parameters of Silent Corticotroph Adenomas With Positive and Negative Adrenocorticotropic Hormone Immunostaining: A Large Retrospective Single-Center Study of 105 Cases. Zhang K; Shou X; Chen H; Qiao N; He W; Chen Z; Shen M; Li S; Zhao Y; Zhang Z; Li Y; Ye H; Wang Y Front Endocrinol (Lausanne); 2020; 11():608691. PubMed ID: 33584540 [TBL] [Abstract][Full Text] [Related]
3. Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review. Langlois F; Lim DST; Yedinak CG; Cetas I; McCartney S; Cetas J; Dogan A; Fleseriu M Pituitary; 2018 Feb; 21(1):32-40. PubMed ID: 29032459 [TBL] [Abstract][Full Text] [Related]
4. ACTH adenomas transforming their clinical expression: report of 5 cases. Zoli M; Faustini-Fustini M; Mazzatenta D; Marucci G; De Carlo E; Bacci A; Pasquini E; Lanzino G; Frank G Neurosurg Focus; 2015 Feb; 38(2):E15. PubMed ID: 25639317 [TBL] [Abstract][Full Text] [Related]
5. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease. Raverot G; Wierinckx A; Jouanneau E; Auger C; Borson-Chazot F; Lachuer J; Pugeat M; Trouillas J Eur J Endocrinol; 2010 Jul; 163(1):35-43. PubMed ID: 20385723 [TBL] [Abstract][Full Text] [Related]
6. Complications after transsphenoidal surgery for patients with Cushing's disease and silent corticotroph adenomas. Smith TR; Hulou MM; Huang KT; Nery B; de Moura SM; Cote DJ; Laws ER Neurosurg Focus; 2015 Feb; 38(2):E12. PubMed ID: 25639314 [TBL] [Abstract][Full Text] [Related]
7. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Cooper O; Ben-Shlomo A; Bonert V; Bannykh S; Mirocha J; Melmed S Horm Cancer; 2010 Apr; 1(2):80-92. PubMed ID: 20717480 [TBL] [Abstract][Full Text] [Related]
8. Pathophysiology and treatment of subclinical Cushing's disease and pituitary silent corticotroph adenomas [Review]. Kageyama K; Oki Y; Nigawara T; Suda T; Daimon M Endocr J; 2014; 61(10):941-8. PubMed ID: 24974880 [TBL] [Abstract][Full Text] [Related]
10. Silent corticotroph adenomas. Ben-Shlomo A; Cooper O Pituitary; 2018 Apr; 21(2):183-193. PubMed ID: 29344907 [TBL] [Abstract][Full Text] [Related]
11. Clinical Parameters to Distinguish Silent Corticotroph Adenomas from Other Nonfunctioning Pituitary Adenomas. Kim D; Ku CR; Park SH; Moon JH; Kim EH; Kim SH; Lee EJ World Neurosurg; 2018 Jul; 115():e464-e471. PubMed ID: 29678704 [TBL] [Abstract][Full Text] [Related]
13. Silent corticotroph pituitary adenomas: clinical characteristics, long-term outcomes, and management of disease recurrence. Strickland BA; Shahrestani S; Briggs RG; Jackanich A; Tavakol S; Hurth K; Shiroishi MS; Liu CJ; Carmichael JD; Weiss M; Zada G J Neurosurg; 2021 Dec; 135(6):1706-1713. PubMed ID: 33962375 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical properties of silent corticotroph adenoma and Cushing's disease. Iino K; Oki Y; Matsushita F; Yamashita M; Hayashi C; Miura K; Nishizawa S; Nakamura H Pituitary; 2007; 10(1):35-45. PubMed ID: 17410413 [TBL] [Abstract][Full Text] [Related]
15. Functioning Crooke Cell Adenomas: Case Series and Literature Review. Giraldi EA; Neill SG; Mendoza P; Saindane A; Oyesiku NM; Ioachimescu AG World Neurosurg; 2022 Feb; 158():e754-e765. PubMed ID: 34800730 [TBL] [Abstract][Full Text] [Related]
16. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas. Katznelson L; Bogan JS; Trob JR; Schoenfeld DA; Hedley-Whyte ET; Hsu DW; Zervas NT; Swearingen B; Sleeper M; Klibanski A J Clin Endocrinol Metab; 1998 May; 83(5):1619-23. PubMed ID: 9589666 [TBL] [Abstract][Full Text] [Related]
17. Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide. Tanaka S; Yamamoto M; Morita M; Takeno A; Kanazawa I; Yamaguchi T; Yamada S; Inoshita N; Oki Y; Kurosaki M; Sugimoto T Endocr J; 2019 Aug; 66(8):701-708. PubMed ID: 31130573 [TBL] [Abstract][Full Text] [Related]
19. Clinical profiles of silent corticotroph adenomas compared with silent gonadotroph adenomas after adopting the 2017 WHO pituitary classification system. Jiang S; Zhu J; Feng M; Yao Y; Deng K; Xing B; Lian W; Wang R; Bao X Pituitary; 2021 Aug; 24(4):564-573. PubMed ID: 33651318 [TBL] [Abstract][Full Text] [Related]
20. Clinicoradiological Parameters and Biochemical and Molecular Alterations Predicting Remission and Recurrence After Surgical Treatment of Corticotroph Adenomas-Cushing Disease. Sadhwani N; Bora SK; Deepa S; Katiyar V; Raheja A; Garg A; Suri V; Tandon N; Sharma MC; Khadgawat R; Suri A World Neurosurg; 2024 Jul; 187():e937-e948. PubMed ID: 38734175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]